Bio-Techne Introduces GMP Small Molecules for Stem Cell Therapy Development
MINNEAPOLIS, Aug. 8, 2018 /PRNewswire/ -- Bio-Techne has introduced a new range of Tocris Bioscience-branded stem cell research compounds produced to cGMP standards, which are suitable for use as ancillary materials in the development of stem cell therapies.
Bio-Techne has a highly-qualified team who have full control over the cGMP process, meaning we can ensure: a quality assured manufacturing system, guaranteed batch-to-batch consistency, traceability from starting material to final product, and consistency of supply. GMP compounds are synthesized in accordance with relevant sections of ICH Q7 guidelines, and are classified as tier 2 risk in the USP <1043> guidelines. The first compounds to be released in our GMP range are SB 431542 and DAPT, which are widely used in stem cell differentiation and reprogramming protocols; these will be followed by Y-27632, CHIR 99021, and XAV 939.
Small molecules have a wide range of applications in stem cell research including reprogramming, differentiation, maintenance, and proliferation. They can also be used in combination or as replacements for growth factors and other proteins. The use of small molecules offers several advantages over alternative methods, including a rapid and reversible action, cell permeability to target intracellular signalling pathways, and concentration-dependent activity so they can be used in different protocols with different outcomes.
Dave Eansor, President of Bio-Techne's Protein Sciences Segment, commented, "We are really excited about the launch of these new GMP stem cell compounds. They will enable scientists to easily transition from the pre-clinical to clinical phase of stem cell therapy development. Alongside Bio-Techne's R&D Systems-branded GMP proteins and antibodies, their use will help advance research into the development of new stem cell therapies."
Bio-Techne Corporation (NASDAQ: TECH) is a leading developer and manufacturer of high quality purified proteins––notably cytokines and growth factors, antibodies, immunoassays, as well as biologically active small molecule compounds and ACD's in situ hybridization detection products --- which are sold to biomedical researchers and clinical research laboratories; these operations constitute the core Biotechnology Division, headquartered in Minneapolis, Minnesota. The Protein Platforms Division manufactures innovative protein analysis tools under the ProteinSimple brand name that greatly automate western blotting and immunoassay practices. The Diagnostics Division manufactures FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and other reagents for OEM customer and clinical customers. Bio-Techne products are integral components of scientific investigations into biological processes and the nature, etiology and progression of specific diseases. They aid in drug discovery efforts and provide the means to develop accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately $643 million in net sales in fiscal 2018 and has over 2,100 employees worldwide. For more information on Bio-Techne and its brands, please visit www.bio-techne.com.
Contact: Dave Eansor, President, Protein Sciences Segment, 612-379-2956
View original content with multimedia:http://www.prnewswire.com/news-releases/bio-techne-introduces-gmp-small-molecules-for-stem-cell-therapy-development-300693604.html
SOURCE Bio-Techne Corporation
Released August 8, 2018